Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030923 | 0.81 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL10177086 | 0.81 | SLC5A2 (0.62) | SLC5A2SLC5A1 | |
| SCHEMBL12167206 | 0.77 | SLC5A2 (0.57) | SLC5A2SLC5A1 | |
| SCHEMBL18466637 | 0.77 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL18466598 | 0.77 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL18466501 | 0.77 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL12167222 | 0.76 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL12167159 | 0.76 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL17969817 | 0.76 | SLC5A2 (0.49) | SLC5A2SLC5A1 | |
| SCHEMBL17969845 | 0.75 | SLC5A2 (0.47) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |